Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01423318 · ClinicalTrials.gov registry record · Phase 1
A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT01423318 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 60 participants.
The verdict
NCT01423318, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the safety and pharmacokinetics of subcutaneous lebrikizumab in healthy Japanese volunteers. Healthy Japanese and Caucasian volunteers will be randomized to receive a single subcutaneous dose of either lebrikizumab or placebo.
Interventions
- DRUG placebo
- DRUG lebrikizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-08 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01423318
The ClinicalTrials.gov registry entry for NCT01423318 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01423318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01423318 about?
NCT01423318 is a clinical study titled "A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers". This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the safety and pharmacokinetics of subcutaneous lebrikizumab in healthy Japanese volunteers. Healthy Japanese and Caucasian volunteers will be randomized to receive a single subcutaneous dose of either lebrikizumab...
What is the current status of trial NCT01423318?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2011-08. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01423318?
The interventions under investigation include: placebo (DRUG), lebrikizumab (DRUG).
Who is sponsoring clinical trial NCT01423318?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.